Altimmune, Inc. (NASDAQ: ALT) is back on many biotech watchlists as investors weigh two competing forces: a near-term clinical and regulatory catalyst calendar for pemvidutide (the company’s lead asset) and a capital-raising backdrop that can quickly change the stock’s risk/reward profile. On Friday, Dec. 12, 2025 , ALT shares are trading in a volatility-heavy tape where options flow, analyst targets, and impending data readouts are all influencing sentiment.

Below is a detailed, publication-ready look at today’s ALT stock action , the latest company and clinical news , Wall Street forecasts , and the key catalysts and risks that matter most right now.

ALT stock snapshot on Dec. 12, 2025

As of Dec. 12, 2025 (latest available quote at…